www.rmcpharma.com
QUALITY RISK MANAGEMENT
Scott Rudge
1 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
OUTLINE
• What is the end product of QRM?• The Target Product Profile• Quality Attributes• Process Map• Cause and Effect Matrix• Failure Modes• Risk Register
12December16 www.rmcpharma.com 2 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
WHAT IS TO GAIN FROM QUALITY RISK MANAGEMENT?
1. Better products for patients2. A useable list of priorities that is visible to
management3. Increased focus on structure/function relationship4. A guideline for process/product development5. Information sharing from R&D to PD
• Start with the end in mind1
1Stephen Covey, Seven Habits of Highly Effective People
12December16 www.rmcpharma.com 3 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
WHAT ARE THE RISKS IN QUALITY RISK MANAGEMENT?
• Risk Assessment is not a substitute for good judgment
• Risks of Failure are not the only basis on which to make a decision• There is excellent research on decision making, and great
tools available that should be used more often• The details will swamp out the signal• Q9 is a set of tools, you must practice them to use
them well
12December16 www.rmcpharma.com 4 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
STRUCTURE OF QUALITY RISK MANAGEMENT
TPP (product design)
CQAs Risk MapCause Effect / Input
Output
Risk Analysis
Risk Register
12December16 www.rmcpharma.com 5 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
TARGET PRODUCT PROFILE
• Describes the biology of the product being developed
• Describes the clinical indication• Describes the typical patient use profile, and their
status (immune compromised, terminal, chronic)• The product packaging and stability requirements• The likely dose and the route of administration• Any additional characteristics of the product that
will make it useable or attractive to the patient
12December16 www.rmcpharma.com 6 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
TPP EMPHASIS
• The TPP, although rarely written, is the heart of process development and is what ties our activities to the care of the patient
• While we are all unlikely to be physicians, it is important for us to understand the character of the patients who will be using our products
• It’s also important for our compassion, to design products that the patient will use, where compliance will be easy and the drug will be effective
12December16 www.rmcpharma.com 7 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
TPP TEAM
• Here is the ideal TPP team:• Clinical• Marketing• Research/Discovery• Toxicology• Product development
• API representative• Drug product representative
• Senior management
• We are not always taught to work well with these groups, especially marketing, but they are critical to designing a great product that patients will use
12December16 www.rmcpharma.com 8 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
TPP GOAL
• Translate a molecule with interesting activity in Discovery studies into a product that will benefit patients and that they will use
12December16 www.rmcpharma.com 9 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
STRUCTURE OF QUALITY RISK MANAGEMENT
TPP (product design)
CQAs Risk MapCause Effect / Input
Output
Risk Analysis
Risk Register
12December16 www.rmcpharma.com 10 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CRITICAL QUALITY ATTRIBUTES
• By definition: A physical, chemical, or biological property that should be within an appropriate limit, range, or distribution to ensure the desired product quality (ICH Q8(R2))
• Identification of potential CQAs
• CQAs are distinct from specifications
• Specifications may not include all CQAs, some may be captured in-process, for example, and some may be process related, like viral clearance and bioburden control, or may be part of product design, like compatibility with plastics in IV sets
• Specifications may include items that are NOT CQAs
12December16 www.rmcpharma.com 11 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CQA IDENTIFICATION AND REVISION
• CQA’s should be identified from the TPP, toxicology studies and from known regulatory requirements• Product/dose related: Endotoxin, DNA, Host cell proteins,
residual solvents, elemental impurities, product concentration, bioactivity, stability and storage conditions
• Toxicology related: substance related impurities, substance related substances, host cell proteins, solvents and elemental impurities
• Regulatory/ industry standards related: viral clearance, bioburden, particulate matter
• When are CQAs revised?• New tox and clinical studies or dosage requirements• Recalls and complaints• PPQ data
12December16 www.rmcpharma.com 12 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
DISCUSSION SLIDE
• Here are two abbreviated product profiles. Discuss some of the attributes that this profile will confer on product Critical Quality Attributes:• Oncology product for late stage liver cancer• IV infusion, 5 grams/day, once weekly for 6 weeks• Patients are immune compromised• Prepared in the hospital pharmacy and delivered to infusion
center in an IV bag
12December16 www.rmcpharma.com 13 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CQA FROM TTP1
• 5 grams per day means very low endotoxin and DNA specifications will be required
• Also, host cell proteins must be low due to the high dose. • Because the patient is immune compromised, risk of infection
is extreme. Bioburden specifications should be tight, viral clearance tight
• Formulation should be compatible with plastic, and preferably with light exposure
• Exposure is acute, so product related impurities are not as critical as they may otherwise be
• Since the patient doesn’t handle the product directly, storage and dosage form may require a pharmacist, vials are OK, frozen storage OK
• Since the product will be diluted, the product concentration in the vial is not critical, must be small enough as to not change the infusion drastically, but this is not a large constraint
12December16 www.rmcpharma.com 14 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
SECOND TPP
• Here is the second hypothetical TPP• Product is for Type 1 diabetes for enhanced control of
blood sugar• Requires patient to mediate dose depending on blood
sugar, up to three times a day• Needs to fit into an insulin pen• Needs to be carried throughout the day by the patient• Dose is approximately 20 mg/dose, three times a day• Administered subcutaneously• Patients are generally lean
12December16 www.rmcpharma.com 15 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CQA FROM TTP2
• Self administered by patient, so:• In use stability at body temperature for a week is critical• Dosage form must be easy to manipulate• Concentration must be at least 20 mg/mL so that dose will be <
1 mL, prefer 200 mg/mL. Tolerance on concentration should be low
• Dose relatively low, so DNA, Endotoxin, HCP can be proportionally higher. Lean patients means the levels maybe should be based on a 50 kg patient, rather than 70 kg
• Neutralizing antibodies are an issue, so the similarity to a native molecule must be very high, product related impurities and aggregate must be very low
12December16 www.rmcpharma.com 16 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
STRUCTURE OF QUALITY RISK MANAGEMENT
TPP (product design)
CQAs Risk MapCause Effect / Input
Output
Risk Analysis
Risk Register
12December16 www.rmcpharma.com 17 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
TRANSLATING CQAS TO CPPS
12December16 www.rmcpharma.com
Unit Operations (1 – 10)
Quality Attributes (1 – 5)
Glycosylation, Man 6P (5)
High Molecular Weight
Aggregates (5)
Low Molecular Weight
Fragments (3)
Charge Isoforms (3)
Bioactivity (5)
Viral Safety
(5)
UF DF 5 5 12 3 5 5Chromatography
Step 1 5 5 3 18 10 30
Chromatography Step 2 5 30 3 6 10 30
Viral Inactivation 5 10 3 3 30 40
Chromatography Step 3 30 5 18 18 10 5
Viral Filtration 5 15 3 3 5 40
18 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
EXPANDING THE RISK SPACE
• This is the first step where the scope of the project can grow exponentially
• For QRM to be usable, efforts must be made to identify not only the highest risks, but also the lowest risks.
• There are risks everywhere, so you have to use common sense and judgment in identifying the right areas for focus
12December16 www.rmcpharma.com 19 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
BIAS ERROR IN CQAS AND PROCESS MAPPING
12December16 www.rmcpharma.com
Identifying attributes and parameters as critical when they are not:
Expenditure of additional resources may be consumed to monitor and control these factors without any benefit to product quality.
Identifying attributes and parameters as noncritical when they are critical:
Lack of adequate control over important quality attributes and process parameters
Misidentification of an attribute or parameter as critical or noncritical
20 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
PROCESS FLOW AND CAUSE AND EFFECT
12December16 www.rmcpharma.com
Further break a process down to sub-steps, for example the cell bank life cycle, shown above. Then risk map again based on the sub-processes
21 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
RISKS IN CELL BANK CREATION
• Lack of clonality (or proof)• Lack of genetic stability• Lack of sterility• Unknown viruses or phages• Rushed clone selection without good
characterization (cell line or product)• Lack of materials control or knowledge
12December16 www.rmcpharma.com 22 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CELL BANK SUB-PROCESS RISK MAP
12December16 www.rmcpharma.com
Unit Operations (1 – 10)
Quality Attributes (1 – 5)
Glycosylation, Man 6P (5)
High Molecular Weight
Aggregates (5)
Low Molecular Weight
Fragments (3)
Charge Isoforms (3)
Bioactivity (5)
Viral Safety
(5)
Bank Creation 25 5 3 3 50 50Cell Bank
Manufacture 5 5 3 3 5 50
Cell Bank Storage 5 5 3 3 5 5
Cell Bank Maintenance 5 5 3 3 30 50
Risks are identified only for clone selection and viral contamination. No other risks need to be analyzed at this time
23 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
STRUCTURE OF QUALITY RISK MANAGEMENT
TPP (product design)
CQAs Risk MapCause Effect / Input
Output
Risk Analysis
Risk Register
12December16 www.rmcpharma.com 24 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CAUSE/EFFECT –INPUT/PROCESS/OUTPUT
• Now the focus is on sorting through details• This can be done ad-hoc, but there are tools for
performing this in a systematic fashion• In Cause/Effect, each aspect of a process or sub-
process is listed, and an effect of failure for each aspect is analyzed according to the CQAs
• In Input/Process/Output analysis each input and output is listed, and the process that works on the I’s is described. Then a huge matrix of I’s, P’s and O’s can be constructed and evaluated.
12December16 www.rmcpharma.com 25 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CAUSE AND EFFECT MATRIX
12December16 www.rmcpharma.com
Key Attribute N/A Y Y Y YRating N/A 9 9 9 9
Process Step Process Parameters
Ass
ay
In-p
roce
ss
purit
yIn
-pro
cess
ch
eck
for
resid
ual
step
-2
Yiel
d
Scor
e
Step 3 Reactor type : QVF reactor 0 0 0 0 0Step 3 Quality of TFA 9 9 9 0 324Step 3 Inert atmosphere (flow of nitrogen rate) 9 9 9 0 324Step 3 Volume of n-heptane (9 vol) 9 9 0 9 324
Cause and effect matrix performed only for the combinations from the process map that are identified as critical, then major.
26 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
IPO (INPUT – PROCESS – OUTPUT)
12December16 www.rmcpharma.com
PROCESSINPUTS OUTPUTS
CONTROLLABLE PARAMETERS
NON-CONTROLLABLE PARAMETERS
(NOISE)
27 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
IPO EXAMPLE
12December16 www.rmcpharma.com 28 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
STRUCTURE OF QUALITY RISK MANAGEMENT
TPP (product design)
CQAs Risk MapCause Effect / Input
Output
Risk Analysis
Risk Register
12December16 www.rmcpharma.com 29 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
FAILURE MODES
12December16 www.rmcpharma.com
CategoryCause of Process/
Parameter Failure
Risk Impact (on Process or
Product)Severity Detection Occurrence
Probability
Primary Risk Control or Mitigation Strategy
Risk Ranking After
Mitigation*
Personnel Parameter entry issue/error
Process Medium High Medium Trained personnel
Low
Sampling contamination
Process and product
High Medium Medium Extensive aseptic training
prior to manufacturing; SIP validation
Low
Off-line read-out Process Low Low Low Personnel training
Low
Equipment Pumps Process Low High Low Calibration/qualification of
pump
Low
Agitation Process High High Low Calibration of system
Low
SIP failure Process High Medium Low Validation of SIP process
Low
CIP failure Process Low Medium Low Validation of CIP process
Low
Steam Process High High Low Validation of utilities
Low
Oxygen Process High Medium Low Received as raw material
with QA release
Low
Air Process High Medium Low Use as clean compressed sterile air with QA release
Low
Carbon dioxide Process High Medium Low Received as raw material
with QA release
Low
30 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
STRUCTURE OF QUALITY RISK MANAGEMENT
TPP (product design)
CQAs Risk MapCause Effect / Input
Output
Risk Analysis
Risk Register
12December16 www.rmcpharma.com 31 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
FAILURE MODES -> RISK MITIGATION
• This is where we use some of the other tools in Q9 can come in, Ishikawa
• DOE, Feasibility Studies and Engineering Batches• Equipment modifications, new technologies• Better procedures, maintenance of equipment and
validation• All manner of methods to mitigate risk
12December16 www.rmcpharma.com 32 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
FAILURE MODES -> RISK REGISTER
• Failure modes analyses populate the risk register• The risk register is a global picture of the risks for a
particular product.• Should encompass risks in all aspects of the
development and deliver of a therapy to patients.• How to manage this without overload is a current
topic in the industry.• Some software is available, I don’t think there is a
consensus product.
12December16 www.rmcpharma.com 33 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
RISK REGISTER, BIG AND SMALL
12December16 www.rmcpharma.com
Category Parameter Risk Occ
urre
nce
Det
ectio
n Seve
rity
RPNMitigation Strategy Owner Status
Source document
storagePrepare
column for next batch
temperature, time,
storage solution
10 10 10 1000
sampling for bioburden and
binding capacity , proper storage
conditions
Smith Open FMEA-Capture Column
contamination
DS: Remove and replace
equipment/materials for difficult to
clean shared product contact
equipment/materials (pH
probes, vent filters, column
frits, non-stainless product contact
parts/materials etc.)
Equipment/ material/parts not replaced
10 10 10 1000
Determine extent of shared equipment is there - bioreactors,
columns, filter holdes. Column frits are
shared (DS). Non stainless parts are not
swabbed or replaced.
Jones Open FMEA Changeover
34 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
RISK METRICS
• The owner of the Risk Register needs to keep metrics• How many risks are reduced?• How many new risks are identified?
• Quarterly and Annual Management Review
12December16 www.rmcpharma.com 35 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
CONCLUSION
• Quality Risk Management from source to operation was diagramed.
• The key is keeping an eye on the output, making it manageable, and keeping it patient and quality focused
• QRM is a great tool for use throughout your development and product lifecycle
12December16 www.rmcpharma.com 36 of 36 RMC Pharmaceutical Solutions, Inc.
ALL RIGHTS RESERVED
Top Related